Cure pharmaceutical announces positive findings from study at cincinnati children's hospital medical center (cchmc) using cure's proprietary, oral thin film (otf) high, single dose vitamin d in pediatric patients pre- and post-hematopoietic stem cell transplantation (hsct)

Oxnard, calif., may 12, 2022 (globe newswire) -- cure pharmaceutical holdings (otc: curr), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced positive finding from a study conducted at cincinnati children's hospital medical center (cchmc) using cure's proprietary, single dose, oral, 40,000 iu vitamin d (branded immund3™ nutri-strips™ in the retail wellness market) in pediatric patients before stem cell therapy. cure's oral vitamin d supplement was found to be more effective than standard supplementation in achieving pre- and post-surgery vitamin d sufficiency, which is critical for reducing immune-mediated organ damage in the children receiving hsct.
CURR Ratings Summary
CURR Quant Ranking